Chatham Capital Group Inc. Sells 395 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Chatham Capital Group Inc. lessened its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,295 shares of the company’s stock after selling 395 shares during the quarter. Chatham Capital Group Inc.’s holdings in Amphastar Pharmaceuticals were worth $1,013,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Smartleaf Asset Management LLC boosted its position in shares of Amphastar Pharmaceuticals by 222.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after purchasing an additional 493 shares in the last quarter. Parkside Financial Bank & Trust boosted its position in shares of Amphastar Pharmaceuticals by 806.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock worth $36,000 after purchasing an additional 871 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Amphastar Pharmaceuticals by 53.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after purchasing an additional 398 shares in the last quarter. Asset Management One Co. Ltd. acquired a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter worth $78,000. Finally, KBC Group NV boosted its position in shares of Amphastar Pharmaceuticals by 43.1% in the 4th quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after purchasing an additional 650 shares in the last quarter. Institutional investors own 65.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Piper Sandler lowered Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $66.00 to $36.00 in a research note on Tuesday, February 4th. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 target price for the company.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $44.42, for a total transaction of $310,940.00. Following the completion of the transaction, the executive vice president now owns 118,469 shares in the company, valued at approximately $5,262,392.98. This trade represents a 5.58 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the transaction, the chief financial officer now owns 97,363 shares of the company’s stock, valued at $2,681,377.02. The trade was a 4.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,231 shares of company stock worth $865,162 in the last 90 days. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $28.32 on Friday. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of 9.44, a price-to-earnings-growth ratio of 2.19 and a beta of 0.81. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The business has a fifty day moving average of $33.89 and a 200 day moving average of $42.12. Amphastar Pharmaceuticals, Inc. has a 1 year low of $26.98 and a 1 year high of $53.96.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.